GleamWall
中文EN

AEMD AETHLON MEDICAL INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 882291 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2027Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY28.3%
TTM EPS YoY137.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-136.8%
ROA-110.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets17.4%
Debt / equity0.00x
Current ratio5.37x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2027Q22026-09-302027Q12026-06-302026Q4*2026-03-312026Q32025-12-312026Q22025-09-302026Q12025-06-302025Q4*2025-03-312025Q32024-12-31
Income statement
Revenue————————
R&D expense$481,000$549,000$589,984$532,782$294,000$524,000$1.33M$240,199
SG&A expense$682,477$662,450$698,016$741,650$521,423$735,358$717,961$816,383
Operating income-$2.68M-$1.58M-$1.93M-$2.06M-$1.51M-$1.79M-$2.00M-$1.81M
Net income-$2.62M-$1.55M-$1.88M-$2.02M-$1.49M-$1.76M-$6.25M-$1.75M
EBITDA-$2.59M-$1.51M-$1.85M-$1.98M-$1.43M-$1.71M-$1.92M-$1.73M
EPS (basic)-2.60-4.02—-2.45-18.70-42.42—-10.05
EPS (diluted)-2.60-4.02—-2.45-18.70-42.42—-10.05
Weighted avg. shares (diluted)1.01M384,705—823,12679,50341,529—174,529
Banking
Net interest income$54,001$31,290—$43,871$22,730$30,532—$59,964
Balance sheet
Cash & equivalents$6.49M$4.93M$5.03M$6.96M$5.85M$3.77M$5.60M$4.83M
Current assets$6.86M$5.61M$5.57M$7.14M$6.25M$4.05M$5.95M$4.97M
PP&E, net$215,126$293,112$356,822$434,179$513,992$593,720$676,220$762,138
Intangibles——$0$138$275$413$550$688
Total assets$7.33M$6.24M$6.33M$8.06M$7.32M$5.31M$7.36M$6.53M
Current liabilities$1.28M$1.04M$1.45M$1.26M$1.40M$1.63M$1.90M$1.77M
Total liabilities$1.28M$1.04M$1.45M$1.34M$1.58M$1.88M$2.24M$2.19M
Shareholders' equity$6.05M$5.20M$4.89M$6.71M$5.75M$3.42M$5.12M$4.33M
Shares outstanding1.61M477,402314,100973,213761,3182.60M201,07413.99M
Cash flow statement
Operating cash flow-$1.74M-$1.90M-$1.75M-$1.87M-$1.66M-$1.71M-$1.67M-$2.01M
Capital expenditure$2,165$9,150$2,051$1,653$0$0-$2,192$2,192
Free cash flow-$1.74M-$1.91M-$1.75M-$1.88M-$1.66M-$1.71M-$1.67M-$2.01M
Investing cash flow-$2,165-$9,150-$2,051-$1,653$0$0$2,192-$2,192
Financing cash flow$3.29M$1.82M-$196,496$2.98M$3.74M-$5,357$2.36M-$7,073
Depreciation & amortization$80,150$72,860$79,547$81,603$79,866$82,637$83,864$83,808
Stock-based compensation$50,000$50,000$61,221$72,442$72,442$72,442$72,443$89,970

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.